<DOC>
	<DOCNO>NCT00133861</DOCNO>
	<brief_summary>The aim study confirm functional improvement obtain treatment spasticity 2 agonist antagonist muscle . The hypothesis treatment muscle give well longer functional improvement treatment one muscle . The target muscle rectus femoris semitendinosus treatment botulinum toxin . Clinical assessment ( passive range motion lower limb , spasticity level , functional scale subjective feel ) gait analysis data ( kinematics kinetics data ) collect . Evaluations take place treatment , 2 month 6 month treatment .</brief_summary>
	<brief_title>Botulinum Toxin Efficiency Spasticity Rectus Femoris Semitendinosus Muscles Functional Agonist Antagonist Muscles</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients 7 17 year old Cerebral palsy child walk ability ( even crutch kneewalker ) allow gait analysis . Patients functional status allow use botulinum toxin target muscle . Patients 7 year old Patients 17 year old Patients botulinum toxin contraindicate Patients receive botulinum toxin within 6 month period begin study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>cerebral palsy child</keyword>
	<keyword>Botulinum toxin</keyword>
</DOC>